earnings

GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M
GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M
Fierce Pharma
GSK
vaccines
earnings
Shingrix
shingles
Flag link:
AbbVie's First Quarter: Trying to Replace Humira Sales
AbbVie's First Quarter: Trying to Replace Humira Sales
Yahoo/Motley Fool
AbbVie
earnings
Humira
Flag link:
What to Expect With Gilead Sciences Inc.'s Q1 Earnings Results
What to Expect With Gilead Sciences Inc.'s Q1 Earnings Results
Motley Fool
Gilead Sciences
earnings
Flag link:
What to Expect with Pfizer's Q1 Results
What to Expect with Pfizer's Q1 Results
Motley Fool
Pfizer
earnings
Flag link:
Allergan: Q1 Results Could Convince Bulls Growth Is Dead
Allergan: Q1 Results Could Convince Bulls Growth Is Dead
Seeking Alpha
Allergan
earnings
Flag link:
BioMarin Cruises While It Waits on Seventh Approval
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Biomarin
pegvaliase
FDA
PKU
earnings
Flag link:
Why Seattle Genetics Jumped Higher Today
Why Seattle Genetics Jumped Higher Today
Motley Fool
Seattle Genetics
earnings
Adcetris
Flag link:
Stryker Q1 beats The Street
Stryker Q1 beats The Street
Mass Device
Stryker
earnings
devices
Flag link:
Sanofi Stumbles as Key Medicines' Sales Spark Growth Concerns
Sanofi Stumbles as Key Medicines' Sales Spark Growth Concerns
Bloomberg
Sanofi
earnings
Flag link:
Biogen’s Spinraza Sales Slow as AveXis and Novartis Pursue SMA Gene Therapy
Biogen’s Spinraza Sales Slow as AveXis and Novartis Pursue SMA Gene Therapy
Xtalks
Biogen
earnings
Spinraza
spinal muscular atrophy
Flag link:
Hey, Takeda shareholders: Shire's Q1 may ease some buyout worries, analysts say
Hey, Takeda shareholders: Shire's Q1 may ease some buyout worries, analysts say
Fierce Pharma
Takeda
Shire
M&A
earnings
Flag link:
Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales
Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales
Investors Business Daily
Vertex Pharmaceuticals
earnings
Flag link:
Ocrevus fuels fast start to year for Roche
Ocrevus fuels fast start to year for Roche
Biopharma Dive
Roche
earnings
Ocrevus
Flag link:
Bristol-Myers profit tops Street view, raises 2018 forecast
Bristol-Myers profit tops Street view, raises 2018 forecast
Reuters
Bristol-Myers Squibb
earnings
Flag link:
AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback
AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback
Marketwatch
AbbVie
earnings
Flag link:
Amgen focuses on migraine launch as growth remains slow
Amgen focuses on migraine launch as growth remains slow
Biopharma Dive
Amgen
earnings
Repatha
Kyprolis
Prolia
Xgeva
Flag link:
Look at our new launches, GSK urges, as its respiratory woes steal the limelight
Look at our new launches, GSK urges, as its respiratory woes steal the limelight
Fierce Pharma
GSK
earnings
HIV
Shingrix
Flag link:
Immunotherapies, biosimilars to dominate next week of earnings
Immunotherapies, biosimilars to dominate next week of earnings
Biopharma Dive
AbbVie
AstraZeneca
Bristol-Myers Squibb
Celgene
Roche
Vertex Pharmaceuticals
Sanofi
earnings
Flag link:
Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib
Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib
Fierce Pharma
Eli Lilly
earnings
baricitinib
Flag link:
Biogen stock drops 2% after Q1 sales miss
Biogen stock drops 2% after Q1 sales miss
Marketwatch
Biogen
earnings
Flag link:

Pages